EGFR and non-small cell lung carcinoma: Furthermore, DYRK1A suppression can promote the degradation of EGFR and reduce the self‐renewal capacity of glioblastoma cells.15 However, whether DYRK1A plays an important role in NSCLC oncogenesis and treatment requires further investigation.